



Fortnightly TAG Mail – resources list

18th July 2024

NSW TAG ACTIVITIES

Invitation to participate in survey: Protocols for critical medicines in NSW public facilities

To be completed by the healthcare professionals familiar with a hospital's/district's/service's protocols for critical care medicine (who may wish to answer as a group of healthcare professionals). It should take no more than 10-15 minutes. Survey closes 24th August 2024.

Survey Link: <https://www.surveymonkey.com/r/PJZ3989>

New open email discussions

-Ongoing infliximab for immune therapy colitis Closes 26th July 2024

Recently completed email discussions

-Feedback for TGA Proposed Updates to Medicine Labelling Rules.

-Implementation of the Guiding Principles for Transition of Young People on Complex and/or Costly Medicines from Paediatric to Adult Care.

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

AJHSP: Mapping the next steps for critical care pharmacists - [link](#)

BJCP: Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants - [link](#)

BJCP: Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings- [link](#)

BMJ: New and emerging treatments for major depressive disorder - [link](#)

BMJ QS: -Frequency and preventability of adverse drug events in the outpatient setting - [link](#)

BMJ QS: Components of pharmacist-led medication reviews and their relationship to outcomes- [link](#)

EHJ: Safety of treating acute pulmonary embolism at home- [link](#)

EJHP: Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis - [link](#)

EJHP: Risk assessment of clinical trial protocols: a tool for hospital pharmacists to reduce human error in experimental drug management - [link](#)

IJCP: Impact of medicine shortages on hospital practice: role of a multidisciplinary medicine shortages team - [link](#)

IJCP: The impact of codeine rescheduling on non-opioid analgesic use by people who regularly use codeine: a prospective cohort study - [link](#)

IJCP: Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes - [link](#)

JAMA IM: Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity - [link](#)

JACCP: Impact of pharmacist-led discharge medication reconciliation on error and patient harm prevention at a large academic medical center - [link](#)

JPPR: Implementation of hospital electronic medical record Patient Friendly Medication Lists and Interim Medication Administration Charts - [link](#)

JPPR: Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals - [link](#)

Lancet ID: Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - [link](#)

MDPI: Factors Determining Quality of Drug Information by Hospital Pharmacies—Results from Five-Year Annual Quality Assessment - [link](#)

MJA: Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)

MJA: Out-of-pocket health care expenses for people with and without cancer, New South Wales, 2020: a cross-sectional study – [link](#) - [editorial](#)

NEJM: Anticipating the Next Pandemic - [link](#)

Pharmacotherapy: Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1- [executive summary](#) - [link](#)

Pharmacotherapy: Update on the clinical applications of SGLTis- [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Agency for Clinical Innovation (ACI), NSW

The latest weekly Evidence Digest can be found [here](#)

AHHA

- Updated Position Statement: Equality for LGBTIQ+ people in health - [link](#)

- Update on Modernising My Health Record Review – [summary report](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- Australian Passive AMR Surveillance: Trends in macrolide resistance in Streptococcus agalactiae and Streptococcus pyogenes – 2006 to 2023 - [link](#)

Australian Institute for Health and Welfare (AIHW)

- Australia's health 2024 – [link](#) – [brief summary](#); Alcohol, tobacco & other drugs in Australia – [update](#)

- Health checks and follow-ups for Aboriginal and Torres Strait Islander people - [link](#)

PBS

- PBAC Public Summary Documents – March 2024 meeting - [5 July 2024](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages

- Australian prescription medicine decision summaries:

-- [Mirena](#) (levonorgestrel) intrauterine device - long-acting reversible contraceptive. The duration for use as a contraceptive has been extended from 5 years to 8 years

-- [Oxlumo](#) (lumasiran) for primary hyperoxaluria type 1 (PH1) in all age groups

-- [Amvuttra](#) (vutrisiran) for hereditary transthyretin-mediated amyloidosis in adults with stage 1 or stage 2 polyneuropathy

-- [Cibinqo](#) (abrocitinib) for moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. Cibinqo can be used with/ without medicated topical therapies for atopic dermatitis

Victorian Institute of Forensic Medicine

- Clinical Communiqué Volume 11 Issue 2 [June 2024](#)

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- Cytisine recommended for use within NHS Wales for smoking cessation - [link](#)

- [Nivolumab](#) not recommended for use within NHS Wales for first-line treatment of deficient mismatch repair / high microsatellite instability oesophageal and gastric cancer

Canadian Agency for Drugs and Technologies in Health

- Somatropin - [link](#)

- Trends in Public Drug Plan Expenditures for Patients With Crohn Disease and Ulcerative Colitis Initiating Targeted Immune Modulator Therapy - [link](#)

Care Quality Commission (UK)

- The safer management of controlled drugs: Annual update 2023 - [link](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

-- Lyfnua (gefapixant citrate) - selective antagonist of the P2X3 receptor for refractory or unexplained chronic cough in adults

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Ocrevus (ocrelizumab) - new subcutaneous formulation for adults with relapsing forms of multiple sclerosis or early primary progressive multiple sclerosis. Patients currently receiving intravenous ocrelizumab may transition to this formulation
- Tolak (fluorouracil) - topical treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade I and II) of the face, ears, and/or scalp in adults
- Uzpruvo (ustekinumab) - pre-filled syringe of biosimilar highly similar to Stelara for moderate to severe plaque psoriasis in adults and children aged ≥ 6 years, psoriatic arthritis (adults) and moderate to severely active Crohn's disease (adults)
- Yorvipath (palopegteriparatide) pre filled pen - prodrug of parathyroid hormone given once daily by subcutaneous injection, is licensed for the treatment of adults with chronic hypoparathyroidism
- Yuflyma (adalimumab) – 20mg prefill biosimilar for same indications as the originator Humira

Future Health

- Building new health system action to reduce obesity: Audit findings of Integrated Care Board Forward Plans - [link](#)

Health Foundation, UK

- What builds good health? - [link](#)

Homecare Association, UK

- Expecting the Unexpected: Homecare providers' views of hospital discharge - [link](#)

Medicines and Healthcare products Regulatory Agency (MHRA)

- MHRA approves vibegron to treat adult patients with Overactive Bladder Syndrome (OAB) - [link](#)
- Capivasertib approved to treat patients with advanced breast cancer - [link](#)
- Ocrelizumab approved as an injection to treat multiple sclerosis in adults - [link](#)

MIMS, UK

- MIMS summary: New once-daily fluorouracil cream launched for actinic keratosis - [link](#)

NHS England

- Children and young people diabetes toolkit - [link](#)
- Framework for managing the response to pandemic diseases - [link](#)

NHS Providers

- Making sense of health inequalities - [link](#)

NHS Scotland

- SMC completes initial assessment of the evidence for birch bark extract gel (Filsuvez®) for treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients ≥ 6 months - [link](#)
- Accepted for use:
 - [Nivolumab with relatlimab](#) (Opdualag®) for first-line advanced melanoma in those aged ≥ 12 years
 - [Pembrolizumab](#) (Keytruda®) in combination with chemotherapy, for first-line HER2-negative gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1
 - [Voretigene neparvovec](#) (Luxturna®) for vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations
- Accepted for restricted use:
 - [Empagliflozin](#) (Jardiance®) for chronic kidney disease in adults
 - [Follitropin delta](#) (Rekovelle®) for controlled ovarian stimulation in women undergoing assisted reproductive technologies
 - [Pegunigalsidase alfa](#) (Elfabrio®) for long-term enzyme replacement therapy in adults with a confirmed diagnosis of Fabry disease
- Not recommended:
 - [Pembrolizumab](#) (Keytruda®) in combination with trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma in adults whose tumours express PD-L1 with a CPS ≥ 1

National Institute for Health and Care Excellence (NICE) UK

- Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over ([TA986](#))
- NICE recommends Hemgenix for severe haemophilia B - [link](#)
- Need for treatment pauses challenged by migraine prevention data - [link](#)
- Improving mood reduces inflammation in inflammatory bowel disease - [link](#)

National Institute for Health and Care Research (NIHR)

- Emollient application from birth to prevent eczema in high-risk children: the BEEP RCT - [link](#)
- Devices for remote continuous monitoring of people with Parkinson's disease: a systematic review and cost-effectiveness analysis - [link](#)

Specialist Pharmacy Services NHS UK

- New product evaluations – [June 2024 update](#)

The King's Fund (UK)

- Realising the potential of integrated care systems - [link](#)

UK Health Security Agency

- Your guide to the RSV vaccine for older adults - [link](#)
- A guide to Respiratory syncytial virus (RSV) vaccination for pregnant women - [link](#)
- Respiratory syncytial virus (RSV) programme: information for healthcare professionals - [link](#)
- UKHSA encourages timely vaccination as whooping cough cases rise - [link](#)
- Immunisations for teenagers and young people - [link](#)

World Health Organisation (WHO)

- Establishing quality specifications for medicines, vaccines and in vitro diagnostics - [link](#)
- Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts) - [link](#)
- WHO global action plan on promoting the health of refugees and migrants, 2019–2030 - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Bavencio (avelumab): information included on ADRs reported during treatment with other immune checkpoint inhibitors, which might also occur during treatment with avelumab
- Buvidal (buprenorphine): opioids can cause sleep-related breathing disorders, and dose reduction can be considered should this occur. Also, presence of traces of natural rubber & latex in product cannot be excluded, and there is a potential risk of allergic reaction in latex sensitive patients
- Camzyos (mavacamten): updated to remove the statement that bioequivalence between strengths has not been confirmed. The prohibition on the use of multiple capsules to achieve a prescribed dose has also been deleted
- Ceftriaxone: hypersensitivity reactions reported with all beta-lactam antibiotics; can also progress to Kounis syndrome (frequency unknown), a serious allergic reaction that can result in myocardial infarction
- Comirnaty (tozinameran) 12+ years, Omicron XBB.1.5 (raxtozinameran), Original/Omicron BA.1 (riltazinameran, tozinameran), Original/Omicron BA.4-5 (tozinameran, famtozinameran) mRNA vaccines updated to include information about, and safety data for, co-administration with Flu vaccine
- Dupixent (dupilumab) pre-filled pen for use in adult & paediatric patients (APPs) aged ≥2 years & pre-filled syringe in APPs aged ≥6 months. In children ≥12 years, dupilumab should be administered by/under supervision of adult & in children age 6 months to <12 years, by a caregiver
- Eviplera (emtricitabine, rilpivirine & tenofovir disoproxil) updated with warning/precaution on bone effects, and reduced bone mineral density has been added as a common potential ADR
- Glycopyrronium bromide: pregnancy & breastfeeding contraindication removed. Can cause thickening of secretions, which may increase risk of respiratory infection & pneumonia so it should be discontinued if pneumonia is present

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Hydrea (hydroxycarbamide): may falsely elevate sensor glucose results from certain continuous glucose monitoring systems, which may lead to missed hypoglycaemic episodes and can also cause hypoglycaemia if sensor glucose results are relied upon to dose insulin
- Keytruda (pembrolizumab): pancreatic exocrine insufficiency and coeliac disease added as rare potential ADRs
- Luforbec (beclometasone dipropionate & formoterol fumarate): pharyngeal erythema (uncommon), increased blood pressure (uncommon), and decreased blood pressure (rare) added as ADRs
- Mekinist: atrioventricular block (including complete block) added as an ADR with frequency “not known” for mono therapy and “uncommon” for combination therapy with dabrafenib
- Non-Drowsy Sinutab (paracetamol, pseudoephedrine) updated to warn of risk of abuse; increased doses may ultimately produce toxicity, and continuous use can lead to tolerance resulting in an increased risk of overdosing. Recommended maximum dose and treatment duration should not be exceeded
- Ovex (mebendazole) Suspension: following oral administration, less than 10% of the dose reaches the systemic circulation (previously stated ~ 20%)
- OxyContin (oxycodone): may cause dysfunction & spasm of the Sphincter of Oddi, raising intrabiliary pressure & increasing risk of biliary tract symptoms & pancreatitis. Therefore, it must be administered with caution in patients with pancreatitis & biliary tract diseases
- Peyona (caffeine citrate): noting it is a clear, colourless, aqueous solution with a pH of 4.7 and an osmolality of 144 to 166 mOsm/kg
- Phenergan (promethazine) must not be used in children <6 years of age due to potential for fatal respiratory depression, psychiatric & central nervous system events. Also highlights that phenothiazines may potentiate the action of other depressants (e.g. opiates, alcohol)
- Phenoxymethylpenicillin Sugar Free should ideally be given half an hour before (or at least three [previously 2] hours after) a meal, and to note excretion of metabolites in human milk presents a risk of candidiasis and also of CNS toxicity due to prematurity of the blood brain barrier
- Prostag (leuprorelin): severe cutaneous adverse reactions reported including Stevens-Johnson syndrome and toxic epidermal necrolysis (unknown frequency), which can be life-threatening or fatal, & metabolic changes linked to GnRH agonist may also include fatty liver disease
- Revestive (teduglutide) for short bowel syndrome in those aged 4 months corrected gestational age and above (previously from 1 year and above): dosing and clinical trial information added
- Rifampicin products (Rifadin; Rifanah): caspofungin included as an interacting medicine; note that after two weeks of repeated administration of rifampicin, trough levels of caspofungin were 30% lower than in adult subjects who received caspofungin alone
- Rinvoq (upadacitinib hemihydrate): updated with long term safety and efficacy data up to week 104 from SELECT-AXIS 2 study for patients with non-radiographic axial spondyloarthritis
- Seroquel (quetiapine): serotonin syndrome added as an ADR. If concomitant treatment with other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases
- Sunitinib: hyperammonaemic encephalopathy added as a potential ADR of unknown frequency. Clinicians are advised to check ammonia levels in patients that develop unexplained lethargy or changes in mental status and treat as clinically appropriate
- Tafinlar (dabrafenib): peripheral neuropathy (including sensory and motor neuropathy) added as a common ADR
- Tecentriq (atezolizumab) injection: coeliac disease added as a rarely occurring ADR
- Tegretol (carbamazepine): maximum daily dose limited to 1200 mg per day for Tegretol Liquid
- Topamax (topiramate) new MHRA safety measures added, including a Pregnancy Prevention Programme, which must be fulfilled in women of childbearing potential, otherwise use would be contraindicated in this patient group
- Yentreve and Cymbalta (duloxetine) hard gastro-resistant capsules: neuroleptic malignant syndrome (NMS) may occur with duloxetine treatment, and that in its most severe form, serotonin syndrome can resemble NMS. Stress cardiomyopathy (Takotsubo cardiomyopathy) added as ADR

EMA

- Glatiramer acetate: anaphylactic reactions may occur months up to years after treatment initiation - [link](#)

- New EU recommendations for GLP-1 receptor agonists to minimise risk of aspiration and pneumonia aspiration during general anaesthesia or deep sedation - [link](#)

MIMS, UK

- New MIMS resource summarises pancreatin options amid supply shortages - [link](#)

Specialist Pharmacy Services NHS UK

- Clinical considerations for patients prescribed clozapine - [link](#)
- Managing the risks associated with patients prescribed clozapine - [link](#)
- Administration of contrast agents under a PGD by multiple HCPs - [link](#)
- Legal mechanisms and contrast agents - [link](#)
- Occupational health services explainer videos - [link](#)
- Preparing to use ustekinumab biosimilar - [link](#)

TGA

- Zactin Tabs (fluoxetine 20 mg dispersible tablets) shortage resolved - [link](#)

PAPERS OF INTEREST

Age and Ageing

- Inappropriate prescribing in older people: not only a patient safety issue but an avoidable source of environmental harm - [link](#)

American Journal of Emergency Medicine

- Efficacy of second-line anticonvulsant agents with adult status epilepticus: A systematic review and network meta-analysis - [link](#)

American Journal of Health-System Pharmacy (AJHSP)

- Impact of connected dispensing technology with advanced analytics in a multicenter health system - [link](#)
- Risk factors for treatment of asymptomatic bacteriuria in a rural health system - [link](#)
- Pharmacotherapy considerations for pediatric acute agitation management in the emergency department - [link](#)
- Central lines, aseptic batching services, and infection rates: A pharmacy-led initiative of intravenous tube priming within a NICU - [link](#)
- A call to action: Studying the shortened duration of ceftriaxone for inpatient management of acute uncomplicated cystitis - [link](#)
- Using quality improvement frameworks to develop, implement, and evaluate a novel ambulatory oncology pharmacy practice model: A descriptive example - [link](#)
- Exploring the therapeutic utility of the factor XIa inhibitor asundexian - [link](#)
- Mapping the next steps for critical care pharmacists - [link](#)
- A national survey of medication utilization for cardiac resuscitation in the emergency department: A survey of emergency medicine pharmacists - [link](#)
- From transthyretin cardiac amyloidosis diagnosis to tafamidis treatment: Association of drop-off with patient sociodemographic characteristics - [link](#)

Annals of Internal Medicine

- Comparative Effectiveness and Safety of Apixaban, Rivaroxaban, and Warfarin in Patients with Cirrhosis and Atrial Fibrillation: A Nationwide Cohort Study - [link](#)
- Effect of Acupuncture for Methadone Reduction: A Randomized Clinical Trial - [link](#)
- Best Practices in Caring for Seriously Ill Patients - [link](#)
- Glucagon-Like Peptide-1 Receptor Agonists and Risk for Suicidal Ideation and Behaviors in U.S. Older Adults with Type 2 Diabetes: A Target Trial Emulation Study - [link](#)

Arthritis & Rheumatology

- 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) Guideline for the Treatment of Interstitial Lung Disease in People with Systemic Autoimmune Rheumatic Diseases - [link](#)

Australian Health Review

- Leveraging existing data to improve antimicrobial resistance-related mortality estimates for Australia - [link](#)

British Journal of Clinical Pharmacology

- Initiation of lipid-lowering therapy as primary prevention of cardiovascular disease in the elderly - [link](#)
- Optimizing anticoagulation therapy for in-hospital patients on direct oral anticoagulants: a single-centre modified Delphi study - [link](#)
- Antidepressant and antipsychotic prescribing in patients with type 2 diabetes in Scotland: A time-trend analysis from 2004 to 2021 - [link](#)
- Infringement of clinical pharmacist's authority - [link](#)
- Economic evaluations of therapeutic drug monitoring interventions in acute hospital-based settings: A systematic review - [link](#)
- Efficacy and safety of androgen receptor inhibitors for treatment of advanced prostate cancer: A systematic review and network meta-analysis - [link](#)
- Steroid–tacrolimus drug–drug interaction and the effect of CYP3A genotypes - [link](#)

British Journal of General Practice

- Breast cancer risk assessment for prescription of menopausal hormone therapy in women with a family history of breast cancer: an epidemiological modelling study - [link](#)
- Cost-utility analysis of molnupiravir for high-risk, community-based adults with COVID-19: an economic evaluation of the PANORAMIC trial - [link](#)
- Should I Take Aspirin? (SITA): randomised controlled trial of a decision aid for cancer chemoprevention - [link](#)

British Medical Journal (BMJ)

- State of the Art Review: New and emerging treatments for major depressive disorder - [link](#)
- Novo Nordisk failed to disclose £7.8m in payments to doctors and others over three years - [link](#)
- Does frailty need a new name? - [link](#)
- Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration - [link](#)

BMJ Open

- Are adverse events higher among patients with acute optic neuritis prescribed glucocorticoids? A retrospective, longitudinal cohort study - [link](#)

BMJ Quality and Safety

- Frequency and preventability of adverse drug events in the outpatient setting - [link](#)
- Components of pharmacist-led medication reviews and their relationship to outcomes: a systematic review and narrative synthesis - [link](#)
- Longitudinal cohort study of discrepancies between prescribed and administered polypharmacy rates: implications for National Aged Care Quality Indicator Programs - [link](#)

Circulation

- Apolipoprotein B: Bridging the Gap Between Evidence and Clinical Practice - [link](#)
- Effects of an Intervention to Improve Evidence-Based Care for People With Diabetes and Cardiovascular Disease Across Sex, Race, and Ethnicity Subgroups: Insights From the COORDINATE-Diabetes Trial - [link](#)
- Equitable Care for Hypertension: Blood Pressure and Patient-Reported Outcomes of the RICH LIFE Cluster Randomized Trial - [link](#)

Cochrane

- Adjunctive antimicrobial photodynamic therapy for treating periodontal and peri-implant diseases - [link](#)
- Treatment of uncomplicated hepatic cystic echinococcosis (hydatid disease) - [link](#)
- Bone-modifying agents for reducing bone loss in women with early and locally advanced breast cancer: a network meta-analysis - [link](#)
- Haloperidol (oral) versus olanzapine (oral) for people with schizophrenia and schizophrenia-spectrum disorders - [link](#)

Diabetes Care

- Sustained 3-Year Improvement of Glucose Control With Hybrid Closed Loop in Children With Type 1 Diabetes While Going Through Puberty - [link](#)
- Rational Pharmacotherapy in Type 2 Diabetes: Danish Data From 2002 to 2020 on Mortality, Diabetes-Related Outcomes, Adverse Events, and Medication Expenses - [link](#)

Drug and Therapeutics Bulletin

- Safety update: more on topical steroid severe adverse effects - [link](#)

EClinical Medicine

- 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study - [link](#)

European Heart Journal

- Heart failure with preserved ejection fraction therapy: combining sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists - [link](#)
- Safety of treating acute pulmonary embolism at home: an individual patient data meta-analysis - [link](#)
- Thromboembolism after coronavirus disease 2019 vaccination in atrial fibrillation/flutter: a self-controlled case series study - [link](#)

European Journal of Hospital Pharmacy

- Taking care of caregivers: enhancing proper medication management for palliative care children with polypharmacy - [link](#)
- Cost-effectiveness of preoperative pharmaceutical care consultations: a 5-year analysis - [link](#)
- Clopidogrel-induced thrombotic microangiopathy: a case report - [link](#)
- Risk assessment of clinical trial protocols: a tool for hospital pharmacists to reduce human error in experimental drug management - [link](#)

Internal Medicine Journal

- Impact of hospital-administered extended-release naltrexone on readmission rates for patients with alcohol use disorder - [link](#)
- Evaluation of early fluoropyrimidine toxicity in solid organ cancer patients: a retrospective observational study in Australia - [link](#)

International Journal of Clinical Pharmacy

- Impact of medicine shortages on hospital practice: role of a multidisciplinary medicine shortages team - [link](#)
- The impact of codeine rescheduling on non-opioid analgesic use by people who regularly use codeine: a prospective cohort study - [link](#)
- The evolving role of pharmacists in depression care: a scoping review - [link](#)
- Anticholinergic burden and health-related quality of life among adult patients in a resource-limited setting: a cross-sectional study - [link](#)
- Anti-CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years - [link](#)
- Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States - [link](#)
- Authors' response to comments on "The efficacy of zuranolone versus placebo in postpartum depression and major depressive disorder: a systematic review and meta-analysis" - [link](#)

- A model for identifying potentially inappropriate medication used in older people with dementia: a machine learning study - [link](#)
- Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes - [link](#)

JAMA

- Essential Tremor - [link](#)
- Patient page: What Are Food Allergies? - [link](#)

JAMA Cardiology

- Efficacy and Safety of Lerodalcibep in Patients With or at High Risk of Cardiovascular Disease: A Randomized Clinical Trial - [link](#)
- Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical Trial - [link](#)
- Dose Reduction of Edoxaban in Patients 80 Years and Older With Atrial Fibrillation: Post Hoc Analysis of the ENGAGE AF-TIMI 48 Randomized Clinical Trial - [link](#)
- Dual vs Single Cardioversion of Atrial Fibrillation in Patients with Obesity: A Randomized Clinical Trial - [link](#)

JAMA Dermatology

- Dupilumab in Adults with Moderate to Severe Atopic Dermatitis: A 5-Year Open-Label Extension Study - [link](#)
- Immunotherapy for Advanced Skin Cancer in Kidney Transplant Recipients—The High-Risk Balancing Act - [link](#)

JAMA Internal Medicine

- Semaglutide vs Tirzepatide for Weight Loss in Adults with Overweight or Obesity - [link](#)

JAMA Network Open

- Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients with Type 2 Diabetes - [link](#)
- Interventions for Weight Management in Children and Adolescents Updated Evidence Report and Systematic Review for the US Preventive Services Task Force - [link](#)

JAMA Neurology

- Direct-Acting Oral Anticoagulants and Antiseizure Medications for Atrial Fibrillation and Epilepsy and Risk of Thromboembolic Events - [link](#)

JAMA Oncology

- Initial Management of BRAF V600E-Variant Anaplastic Thyroid Cancer: The FAST Multidisciplinary Group Consensus Statement - [link](#)

JAMA Ophthalmology

- Risk of Non-arteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide - [link](#)

J Am Coll Clin Pharm

- Impact of pharmacist-led discharge medication reconciliation on error and patient harm prevention at a large academic medical center - [link](#)

Journal of Clinical Oncology

- Denosumab Prevents Bone Loss and Microarchitectural Deterioration in Premenopausal Women with Breast Cancer Receiving Estradiol Suppression Therapy: A Randomized Controlled Trial - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Sepsis call emergency department pharmacist service: a single healthcare network cohort study - [link](#)
- Pharmacist's role in influenza immunisation: a scoping review - [link](#)

- Implementation of hospital electronic medical record Patient Friendly Medication Lists and Interim Medication Administration Charts - [link](#)
- Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals - [link](#)

Lancet

- The CONCORD–Lancet Global Commission on Cancer - [link](#)
- Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment - [link](#)

Lancet Diabetes & Endocrinology

- Efficacy and safety of SGLT2 inhibitors with and without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised controlled trials - [link](#)
- Precision nutrition: a step too far? - [link](#)

Lancet Gastroenterology and Hepatology

- Portal vein thrombosis: diagnosis, management, and endpoints for future clinical studies - [link](#)

Lancet Haematology

- Diagnosis and management of Evans syndrome in adults: first consensus recommendations - [link](#)

Lancet Infectious Diseases

- Comparative effectiveness of combination therapy with nirmatrelvir–ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir–ritonavir in patients hospitalised with COVID-19: a target trial emulation study - [link](#)

Lancet Oncology

- Interpretable artificial intelligence to optimise use of imatinib after resection in patients with localised gastrointestinal stromal tumours: an observational cohort study - [link](#)
- NHS cancer services and systems—ten pressure points a UK cancer control plan needs to address - [link](#)
- Clinical benefit, reimbursement outcomes, and prices of FDA-approved cancer drugs reviewed through Project Orbis in the USA, Canada, England, and Scotland: a retrospective, comparative analysis – [link](#)

Lancet Respiratory Medicine

- Rethinking bronchiectasis as an inflammatory disease - [link](#)
- Nasal sprays and behavioural interventions compared with usual care for acute respiratory illness in primary care: a randomised, controlled, open-label, parallel-group trial - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Factors Determining Quality of Drug Information by Hospital Pharmacies—Results from Five-Year Annual Quality Assessment - [link](#)
- Adapting the Opening Minds Stigma Scale for Healthcare Providers to Measure Opioid-Related Stigma - [link](#)
- Exploring the Perceptions and Behaviours of UK Prescribers Concerning Novel Lipid-Lowering Agent Prescriptions: A Qualitative Study - [link](#)

Medical Journal of Australia

- National Hypertension Taskforce of Australia: a roadmap to achieve 70% blood pressure control in Australia by 2030 - [link](#)
- Living evidence syntheses: the emerging opportunity to increase evidence-informed health policy in Australia - [link](#)
- Out-of-pocket health care expenses for people with and without cancer, New South Wales, 2020: a cross-sectional study – [link](#) - [editorial](#)

New England Journal of Medicine

- Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer - [link](#)

- Nirsevimab and Hospitalization for RSV Bronchiolitis - [link](#)
- Malnutrition in Adults - [link](#)
- Anticipating the Next Pandemic - [link](#)

Neurology

- Efficacy of Atogepant in Chronic Migraine with and without Acute Medication Overuse in the Randomized, Double-Blind, Phase 3 PROGRESS Trial - [link](#)

Pediatrics

- Infantile and Very Early Onset Inflammatory Bowel Disease: A Multicenter Study - [link](#)
- Acetaminophen for Patent Ductus Arteriosus and Risk of Mortality and Pulmonary Morbidity - [link](#)
- The Importance of Timing When Evaluating PDA Treatment Outcomes - [link](#)
- Quality Improvement Interventions to Prevent Intraventricular Hemorrhage: A Systematic Review - [link](#)
- Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine - [link](#)
- Initiation of Buprenorphine Treatment of Opioid Use Disorder in Pediatric Emergency Departments - [link](#)

Pharmaceutical Journal

- Scottish government publishes prescribing guidance aiming to save millions of pounds - [link](#)

Pharmacotherapy

- Consensus recommendations for use of long-acting antiretroviral medications in the treatment and prevention of HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An [executive summary](#) - [link](#)
- Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection - [link](#)

Prescriber UK

- Antipsychotics: beyond dopamine - [link](#)
- Deprescribing in people living with frailty, multimorbidity and polypharmacy - [link](#)

Thorax

- Antibiotic pharmacokinetics in infected pleural effusions - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 167](#) – Diagnosis and management of obstructive sleep apnoea in adults

Purple Pen Podcast

- [PPP 163](#) - Monoclonal Antibodies

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC) - NMS 2024 – save the date, 19 November 2024 - [link](#)

Australian Healthcare and Hospitals Association (AHHA)

- Enabling hospitals and healthcare leaders to advance their sustainability journey, FREE WEBINAR, Thursday 25 July 16:00-17:00 AEST – [register](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024

NSW TAG ACTIVITIES

Current Email Discussions

- Feedback for TGA Proposed Updates to Medicine Labelling Rules. Closes 8th July 2024
- Implementation of the Guiding Principles for Transition of Young People on Complex and/or Costly Medicines from Paediatric to Adult Care. Closes 12th July 2024

Recently Completed Email Discussions

- Virtual Pharmacy Service for Patients being discharged from Hospital
- Shingrix (updated following TAG General meeting 19th July)
- Local protocols for COVID-19 antivirals.

Coming soon: Survey about protocols for critical care medicines.

Contact Sasha Bennett at sasha.bennett@svha.org.au for further information about any email discussions, publications or upcoming meetings.

EDITOR'S PICKS

- AJHP: Optimizing discharge antimicrobial therapy - [link](#)
- AJHP: Impact of automated alerts on discharge opioid overprescribing after general surgery - [link](#)
- AJHP: Effect of pharmacist care on clinical outcomes and therapy optimization in perioperative settings - [link](#)
- BJCP: Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet- α , protamine) - [link](#)
- BJCP: Management of serotonin syndrome (toxicity) - [link](#)
- BJCP: Moderate and serious adverse reactions to antimicrobials among hospitalized children: A systematic review - [link](#)
- BMJ: Philip Morris: Leaked documents show how company tries to influence science and policy on heated tobacco - [link](#)
- BMJ QS: Viewpoint: Need to systematically identify and mitigate risks upon hospitalisation for patients with chronic health conditions - [link](#)
- CATAG: Off label medicines consumer counselling tool - [link](#)
- CATAG: Preventing progression to persistent pain toolkit- [link](#)
- Circulation: CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy- [link](#)
- DC: Hyperglycemic Crises in Adults With Diabetes: A Consensus Report - [link](#)
- EHJ: - Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies- [link](#)
- EjHP: A single harmonised pharmacy process to improve clinical trial set-up times - [link](#)
- IJQHC: Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)
- IMJ: Tocilizumab use in giant cell arteritis: comparing PBS eligible and ineligible cases in SA - [link](#)
- JAMA IM: Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data - [link](#)
- JAMA Psych: Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia - [link](#)
- JAGS: Antibiotics for delirium in older adults with pyuria or bacteriuria: A systematic review - [link](#)
- Lancet Neur: Sleep and sleep disorders in people with Parkinson's disease - [link](#)
- MJA: - Contextualising the benefits and risks of anti-amyloid therapy for patients with Alzheimer disease and their care team - [link](#)
- Nature Medicine: Benefits for children with suspected cancer from routine whole-genome sequencing - [link](#)
- Pediatrics QS: A Quality Initiative to Improve Appropriate Medication Dosing in Pediatric Patients with Obesity - [link](#)

OTHER NEWS

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988
Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au
An initiative of NSW clinical pharmacologists & pharmacists
ABN: 82 707 308 091

NSW Health

- Warning: Hospitalisations after consuming Uncle Frog's Mushroom Gummies - [link](#)
- Three new mpox cases detected in NSW - [link](#)
- NSW Health warns of high seasonal influenza activity - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

ACSQHC Radar Issue 1 July 2024 - [link](#)

- Nirmatrelvir and ritonavir (Paxlovid®) and molnupiravir (Lagevrio®) for COVID-19 (amended PBS listing)
- Type 2 diabetes mellitus (T2DM) medicines (amended PBS restrictions).

Agency for Clinical Innovation, NSW (ACI)

The latest weekly Evidence Digest can be found [here](#)

Australian Institute for Health and Welfare (AIHW)

- Health checks and follow-ups for Aboriginal and Torres Strait Islander people - [link](#)
- Australia's Health 2024- [link](#)
- Medicare Benefits Scheme funded services: monthly data- [link](#)
- Injury in Australia - [link](#)

CATAG

- **Collaborating with consumers: off-label medicines consumer counselling tool** based on the [Rethinking medicines decision-making in Australian Hospitals](#) to support Medicines and Therapeutics Advisory Committees in implementing the Guiding Principles for the quality use of off-label medicines alongside consumers. It is designed to assist hospital-based health professionals and promote shared-decision making when considering treatment with an off-label medicine. It is written in plain English to suit a wide audience and explains the important information consumers need to know about off-label medicines - [link](#)

- **MAIA: Preventing progression to persistent pain toolkit**- [link](#)

CATAG has developed a Preventing progression persistent pain toolkit for Medicines and Therapeutics Advisory Committees and hospitals. The toolkit can assist in increasing understanding of the nature of pain and provide strategies to prevent progression to persistent pain. The toolkit supports the implementation of local stewardship opioid analgesic programs and promotes effective patient-centred education across the perioperative continuum of care. The toolkit includes: [Practice tool](#) to guide Medicines and Therapeutics Advisory Committees [Teaching tool](#) that can be used by clinical educators; it provides a clinical example of opportunities to prevent progression to persistent pain.

Next CATAG Meeting: 25th July 10am- noon.

MIMS monthly updates

- New Products
- [Etrasimod](#) (as arginine) for adults with moderately to severely active UC who have had inadequate response, loss of response or intolerance to conventional, biologic or Janus kinase inhibitor therapies. Velsipity is contraindicated in patients who in the last 6 months, have experienced a myocardial infarction, unstable angina pectoris, stroke, transient ischemic attack, decompensated heart failure requiring hospitalisation, or New York Heart Association class III/IV heart failure; in patients with a history or presence of Mobitz type II second-degree or third-degree atrioventricular block, sick sinus syndrome, or sino-atrial block, unless the patient has a functioning pacemaker; during pregnancy and in women of childbearing potential not using effective contraception; in breastfeeding women; and in active malignancies.
- [Spesolimab](#) (rch) (Spevigo) is a humanised antagonistic monoclonal immunoglobulin G1 antibody blocking human interleukin-36 receptor (IL36R) signalling for flares in adult patients with generalised pustular psoriasis
- New Presentation

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Semaglutide ([Wegovy FlexTouch](#)) now available as a product specifically indicated for weight management as an adjunct to a reduced-energy diet and increased physical activity for chronic weight management (including weight loss and weight maintenance) in adults with an initial Body Mass Index (BMI) of ≥ 30 kg/m² (obesity), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity; and for weight management in adolescents ages 12 years and above with initial obesity [(BMI \geq 95th percentile) as defined on sex and age-specific BMI growth charts (CDC.gov)] and body weight above 60 kg
- New Indication
- Tozinameran and famtozinameran ([Comirnaty Original](#)/Omicron BA.4-5) now indicated (with provisional approval) for active immunisation to prevent COVID-19 in individuals 6 months of age and older in accordance with official recommendations

PBS

- Expansion of the CTG PBS Co-Payment Program - [link](#)

TGA

- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- ORENCIA abatacept 125 mg solution for injection in pre-filled pen (Germany) - Not on the ARTG but approved for import and supply in Australia until 15/12/2024 due to a shortage of another medicine or for public health reasons
- AusPARs:
 - [ADCETRIS](#) (brentuximab vedotin) approved for the treatment of Hodgkin lymphoma in patients with previously untreated CD30+ Stage III or Stage IV Hodgkin lymphoma
 - [NUVAXOVID](#) approved for the prevention of coronavirus disease 2019 (COVID-19) caused by SARSCoV-2 in individuals 12 years of age and older
 - [XEOMIN](#) (Botulinum toxin type A) approved for the treatment of chronic sialorrhea (hypersalivation or excessive drooling) in children and adults
 - [ERWINASE](#) indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of patients with acute lymphoblastic leukaemia
 - [Givlaari](#) (givosiran sodium) for treatment of acute hepatic porphyria
- Australian prescription medicine decision summaries:
 - [TRUQAP](#) (capivasertib), in combination with fulvestrant, is for adults with locally advanced or metastatic breast cancer
 - [EBGLYSS](#) (lebrikizumab) or moderate to severe atopic dermatitis in patients older than 12 years.
 - [VELSIPITY](#) (Etrasimod) treats moderately to severely active ulcerative colitis
 - [TEVIMBRA](#) (tislelizumab) for patients with various types of oesophageal squamous cell carcinoma and non-small cell lung cancer
- Registration of [new or extended uses](#) of registered medicine:
 - [KEYTRUDA](#) ; [COMIRNATY ORIGINAL/OMICRON](#) ; [SAIZEN](#) ; [BIMZELX](#) ; [DYMISTA/ DYLASTINE](#) ; [ONIVYDE](#) ; [KEYTRUDA](#) ; [JARDIANCE](#) ; [TRIKAFTA](#) ; [RYEQO](#) ; [ULTOMIRIS](#) ; [ADCETRIS](#) ; [PREVENAR](#) ; [OPDIVO](#) ; [WEGOVY](#)
- Registration of [new chemical entities](#) in Australia:
 - [AMVUTTRA](#) ; [TEVIMBRA](#) ; [VELSIPITY](#) ; [EBGLYSS](#) ; [TRUQAP](#) ; [CIBINQO](#) ; [TERIPARATIDE RBX/ RITOSA/ TERIPARATIDE SUN](#) ; [LOKELMA](#) ; [NELARABINE-REACH](#) ; [ABRYSVO](#) ; [HEMGENIX](#) ; [WINLEVI](#) ; [VEOZA](#) ; [VERDYE](#) ; [SPY AGENT GREEN](#) ; [ERWINASE](#) ; [AREXVY](#)
- Registration of [new generic medicines](#) and [new biosimilar medicines](#):
 - [MEROPENEM-AFT](#) ; [RASAGILINE JAMP/ RASAGILINE GXMED](#) ; [CIPFOSIN/ CIPLA FOSFOMYCIN](#) ; [PALIPERIDONE-TEVA](#) ; [NOVADAC ONCE DAILY GEL](#) ; [URSODOX GH/ URSODOX LAPL](#) ; [ENZALINE/ LUTACIP/ ENZACIP/ CIP ENZALUTAMIDE](#) ; [BENZYL PENICILLIN KABI](#) ; [GONADRON/ TESTOSTERONE RBX/ TESTOSTERONE SUN](#) ; [OXONAL](#) ; [ATOVACUE](#) ; [CIP APIXABAN/ XABANIL/ APIXABAN CIPLA/ APIXAIR](#) ; [PLERIXAFOR-AFT](#) ; [PIPTAZ MEDICIANZ/ PIPTAZ MEDSURGE](#) ; [FULVESTRANT EUGIA/ EUG-FULVESTRANT/ FULVESTRANT EPSL](#) ; [WEZLANA](#) ; [ONBEVZI](#)

REPORTS AND PUBLICATIONS – INTERNATIONAL

British National Formulary

- BNF/BNFC newsletter: [June 2024](#)

electronic Medicines Compendium (eMC) (UK)

- [New products](#)

- Campona Airmaster (salmeterol, fluticasone propionate) for asthma where use of a combination product (long- acting β 2 agonist and inhaled corticosteroid) is appropriate, and also for the symptomatic treatment of patients with COPD, with a FEV1 <60% predicted normal and repeated exacerbations.
- Cytisine 1.5 mg tablets - similar to nicotine, but weaker, allowing for a gradual reduction of nicotine dependence by relieving withdrawal symptoms. Licensed for smoking cessation & reduction of nicotine cravings in smokers willing to stop smoking.
- Fluenz Trivalent nasal spray suspension Influenza vaccine (live attenuated, nasal) - licensed for the prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. Use should be based on official recommendations.
- Melatonin Orion generic tablets licensed for short-term treatment of jet lag in adults and for insomnia in children and adolescents aged 6– 17 years with ADHD where sleep hygiene measures have been insufficient.

-[Updated SPCs](#)

- Rabipur pre-filled syringe (rabies vaccine) - updated to include a 2 dose regimen for immunocompetent patients on day 0 and day 7
- Veltassa (Patiromer) now licensed for the treatment of hyperkalaemia in adolescents aged 12-17 years, as well as in adults. A new 1g powder for oral suspension formulation is also now available
- VeraSeal (human fibrinogen, human thrombin) - information on use in children, including a note that application of the product must be individualised by the treating physician, with doses ranging from 0.6 to 12mL in the paediatric clinical trial. Details of the trial have been added to section 5.1
- Xtandi (enzalutamide) - licence extension for use as monotherapy or in combination with androgen deprivation therapy for the treatment of adult men with high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage-radiotherapy

European Medicines Agency (EMA)

- European CHMP recommends
- first nasal adrenaline spray for emergency treatment against allergic reactions - [link](#)
- [sotatercept](#) (Winrevair) to treat adults with pulmonary arterial hypertension (PAH)
- Duchenne muscular dystrophy medicine Translarna - [link](#)
- revoking conditional marketing authorisation for [obeticholic acid](#) (Ocaliva)
- [crovalimab](#) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH)
- [durvalumab olaparib](#) for the treatment of endometrial cancer
- [epcoritamab](#) for the treatment of adults with relapsed or refractory follicular lymphoma
- [erdafitinib](#) for urothelial carcinoma harbouring susceptible FGFR3 genetic alterations
- [faricimab](#) for the treatment of retinal vein occlusion
- [flortaucipir](#) (18F) for the diagnosis of Alzheimer's disease
- [isavuconazole](#) for use in paediatric patients
- [mirabegron](#) (Betmiga) for use in children and adolescents with neurogenic detrusor overactivity
- [peginterferon alfa-2a](#) for the treatment of polycythaemia vera and essential thrombocythaemia
- [setmelanotide](#) for use in children aged 2 years and above
- [mResvia](#) vaccine [nirsevimab](#) for prevention of lower respiratory tract (LRT) disease caused by respiratory syncytial virus
- [crizotinib](#) to include treatment of children from 1 year of age
- [odronextamab](#) (Ordspono) for treatment of follicular lymphoma and diffuse large B-cell lymphoma
- [Enzalutamide Viatris](#), generic and bioequivalent to Xtandi, for prostate cancer
- [Nilotinib Accord](#), generic and bioequivalent to Tassigna, for Philadelphia chromosome positive chronic myelogenous leukaemia
- [ustekinumab](#) (Steqeyma) biosimilar to Stelara, for the treatment of adults with moderately to severely active Crohn's disease, plaque psoriasis, paediatric plaque psoriasis and psoriatic arthritis
- Company withdraws application for a marketing authorisation of [Dabigatran etexilate Teva](#) in the EU
- European CHMP adopts a change to the existing indication for [Infanrix Hex](#)

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- refusal of marketing authorisation for [masitinib](#) for amyotrophic lateral sclerosis (ALS)
- refusal of marketing authorisation for [pegcetacoplan](#) (Syfovre) for geographic atrophy caused by age-related macular degeneration (AMD)
- [Lorazepam Macure](#) 4 mg/ml, solution for injection: CHMP opinion on update to include control of status epilepticus in adults, adolescents and children from 1 month of age

Food and Drug Administration (FDA) USA

- New Drug approvals
- treatment for adults with Alzheimer's disease - [Kisunla](#) (donanemab-azbt)
- epcoritamab-bysp for relapsed or refractory follicular lymphoma - epcoritamab-bysp ([Epkiny](#))
- treatment for chronic inflammatory demyelinating polyneuropathy (CIDP) in adults - [Vyvgart Hytrulo](#) (efgartigimod alfa and hyaluronidase-qvfc)
- [adagrasib](#) with cetuximab for KRAS G12C-mutated colorectal cancer
- Ohtuvayre ensifentrine to treat chronic obstructive pulmonary disease
- Piasky Crovalimab-Akkz for adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg – [PI/label](#)

General Pharmaceutical Council

- Statement on self-selection of pharmacy medicines - [link](#)

Health Foundation, UK

- Priorities for an AI in health care strategy - [link](#)

MIMS, UK

- More than 18,500 inhalers recycled over six months in pioneering pharmacist-led pilot - [link](#)

NHS England

- Clinical commissioning policy statement (2317): treatment for defined patients with rifampicin resistant (RR) tuberculosis (TB), multidrug-resistant (MDR) TB, pre-extensively drug-resistant (pre-XDR) TB and extensively drug-resistant (XDR-TB) including bedaquiline and delamanid (all ages) - [link](#)
- Clinical commissioning policy: bedaquiline, pretomanid, linezolid +/- moxifloxacin (BPaLM/BPaL) for patients aged ≥14 years with suspected, functional or confirmed rifampicin resistant tuberculosis (TB), multidrug-resistant TB or pre-extensively drug resistant TB - [link](#)

National Institute for Health and Care Excellence (NICE) UK

- QuiremSpheres for treating unresectable advanced hepatocellular carcinoma ([TA985](#))

National Institute for Health and Care Research (NIHR)

- Interventions for primary prevention of cardiovascular disease: umbrella review of systematic reviews - [link](#)
- Cefiderocol for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model - [link](#)

Nuffield Trust, UK

- What health and care need from the next government: #4 – Improving access to treatment - [link](#)

Professional Record Standards Body, UK

- New transfer of care toolkit - [link](#)

Specialist Pharmacy Services NHS UK

- Using domperidone for low milk supply - [link](#)
- Hormone replacement therapy (HRT): resources for answering questions – [link](#)
- SPS Spotlight Monthly Digest – [June 2024](#)
- New Medicines News [June 2024](#)

UK Health Security Agency

- Updated antimicrobial intravenous-to-oral switch: criteria for prompt switch - [link](#)
- Administration of human normal immunoglobulin (HNIG) for measles post-exposure prophylaxis - [link](#)
- Guidance - Complete routine immunisation schedule – [link](#)
- Guidance - Immunoglobulin: when to use - [link](#)

World Health Organisation (WHO)

- WHO clinical treatment guideline for tobacco cessation in adults - [link](#)
- World Health Organization (WHO) issues warning on falsified medicines used for diabetes treatment and weight loss - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- [Revised SPCs](#)

- Enbrel (etanercept) - frequency of adverse drug reaction 'glomerulonephritis' as rare
- Exforge (amlodipine besilate, valsartan) – risk of drug-drug interaction between amlodipine and tacrolimus that may increase blood levels of tacrolimus with concomitant use. Tacrolimus blood level monitoring is recommended and dose adjustment when appropriate
- Cell-based Quadrivalent Influenza Vaccine (Surface Antigen, Inactivated) Seqirus - strains in the qualitative and quantitative composition section updated for Northern Hemisphere season 2024-2025
- Finlee (dabrafenib mesilate) - peripheral neuropathy as an ADR (frequency not specified). Although this (& certain other ADRs) only been reported in adults, safety profile in children is largely consistent
- Ibrance (palbociclib) – Palbociclib/statins interaction may increase the risk of rhabdomyolysis due to increased statin plasma concentration. Increased blood creatinine added as a common ADR
- Jentadueto (metformin hydrochloride, linagliptin) - use in children and adolescents not recommended; clinical trial related information included stating that no significant improvement on HbA1c levels was provided with use of linagliptin in the paediatric population
- Libtayo (cemiplimab) - immune checkpoint inhibitor class effects added advising on cases of coeliac disease and pancreatic exocrine insufficiency reported during treatment with other PD-1/PD-L1 inhibitors
- Luxturna (voretigene neparvovec) - chorioretinal atrophy (which includes retinal degeneration, retinal depigmentation and injection site atrophy) added as an ADR of unknown frequency. This was reported in post marketing studies and is progressive in some patients
- Numeta G19%E (parenteral nutrition) - further information on 'fat overload syndrome' added, including that it has been associated with metabolic acidosis and respiratory distress in neonates & infants, & that severe cases treated with exchange transfusions have been reported
- Nuwiq (simoctocog alfa) - information about sodium content, anaemia and chest pain added as 'uncommon' possible ADRs
- Oxycontin (oxycodone) - Use with caution in patients with pancreatitis and biliary tract disease. Dysfunction and spasm of Sphincter of Oddi included as possible ADR, 'frequency not known'
- Rizatriptan - moderate amount of data on pregnant women indicate no malformative toxicity following first trimester exposure. There are limited data in relation to use in the second and third trimester; use may be considered during pregnancy, if clinically necessary
- Spexotras (trametinib dimethyl sulfoxide) - peripheral neuropathy added as an ADR (frequency not specified). Although this (& certain other adverse effects) only been reported in adults, safety profile in children is largely consistent
- Targinact (oxycodone hydrochloride, naloxone hydrochloride dihydrate) - information on drug withdrawal syndrome, including symptoms, the need to taper the dose gradually when stopping therapy, and the fact that if taken during pregnancy, there is a risk that newborn infants will experience neonatal withdrawal syndrome
- Xromi (hydroxycarbamide) - recommended duration of contraception in male & female patients following the end of treatment with hydroxycarbamide should be 3 & 6 months, respectively. Both should be advised to use contraceptive measures before, during & after treatment
- Risk minimisation materials
- [Lecigon](#) (levodopa, carbidopa monohydrate, entacapone) intestinal gel - materials to inform healthcare providers (HCPs) & patients about the GI, device and procedure-related risks associated

with Lecigon®, to educate HCPs on PEG-J and NJ tube insertion procedures, and to inform HCPs & patients about aftercare for long-term PEG-J placement
-- topiramate products: Pregnancy Prevention Programme - A number of resources are now available aimed at minimising pregnancy exposure during treatment with topiramate. Educational materials for patients include a patient guide, risk awareness form and patient card

EMA

- EU actions to tackle shortages of GLP-1 receptor agonists - [link](#)

Health Canada – MedEffect Notice

- Health Product InfoWatch, [June 2024](#)

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- Drug Safety Update June 2024

-- Topiramate (Topamax): introduction of new safety measures, including a Pregnancy Prevention Programme - [link](#)

-- Warfarin: be alert to the risk of drug interactions with tramadol - [link](#)

Medsafe (New Zealand Medicines and Medical Devices Safety Authority)

- Outcome of Clozapine Survey/Consultation 2023 - [link](#)

MIMS monthly updates

- New Contraindications

-- Bupropion hydrochloride ([Zyban SR](#)) is now contraindicated in children

-- Rifampicin ([Rifadin](#)) is now contraindicated for concomitant administration with lurasidone

Specialist Pharmacy Services NHS UK

- Medicines suitable for adults with swallowing difficulties, updated 20 June 2024: AVE inhibitors, ARBs, SSRIs - [link](#)

- Searching for presence or absence of an excipient in medicines - [link](#)

- Understanding excipients in medicines - [link](#)

- Medication Safety Update – [June 2024](#)

TGA

- Update on oral opioids - [link](#)

- Product Information safety updates - [June 2024](#)

- Medicines containing *Andrographis paniculata* safety advisory - [link](#)

- Compounded colic preparations containing *Atropa belladonna* - [link](#)

PAPERS OF INTEREST

Age and Ageing

- Investigating the link between antipsychotic use and post-stroke infections in older people: multi-centre propensity score analysis - [link](#)

American Journal of Health-System Pharmacy (AJHP)

- Optimizing discharge antimicrobial therapy: Evaluation of a transitions of care process and electronic scoring system for patients with community-acquired pneumonia or chronic obstructive pulmonary disease - [link](#)

- Impact of automated alerts on discharge opioid overprescribing after general surgery - [link](#)

- Effect of pharmacist care on clinical outcomes and therapy optimization in perioperative settings: A systematic review - [link](#)

- Comparison of clevidipine vs nicardipine in the treatment of hypertensive urgency and emergency in critically ill patients - [link](#)

- Towards consensus recommendations for pharmacogenetics testing - [link](#)

Annals of Internal Medicine

Advancing quality use of medicines in NSW public hospitals and the wider community since 1988

Ph: 0407418 072 | Email: nswtag@stvincents.com.au | www.nswtag.org.au

An initiative of NSW clinical pharmacologists & pharmacists

ABN: 82 707 308 091

- Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease: A Systematic Review and Retrospective Individual Participant–Level Meta-analysis of Clinical Trials - [link](#)
- Medication-Induced Weight Change Across Common Antidepressant Treatments: A Target Trial Emulation Study - [link](#)

Arthritis & Rheumatology

- A Comparison of Gout Flares with the Initiation of Treat-to-Target Allopurinol and Febuxostat: A Post-hoc Analysis of a Randomized Multicenter Trial - [link](#)
- Association of Cardiovascular Outcomes with Low-Dose Glucocorticoid Use in Patients with Rheumatoid Arthritis - [link](#)

British Journal of Clinical Pharmacology

- The pharmacokinetic differences between 10- and 15- μ g daily vitamin D doses - [link](#)
- Anticoagulation reversal (vitamin K, prothrombin complex concentrates, idarucizumab, andexanet- α , protamine) - [link](#)
- Management of serotonin syndrome (toxicity) - [link](#)
- Anticholinergic deprescribing: A case report demonstrating improved cognition and function with minimal adverse withdrawal effects - [link](#)
- Cassia angustifolia and tacrolimus interaction in a liver transplant patient, a case report - [link](#)
- Moderate and serious adverse reactions to antimicrobials among hospitalized children: A systematic review - [link](#)

British Journal of General Practice

- Patients' perspectives about the role of primary healthcare providers in long-term opioid therapy: a qualitative study in Dutch primary care - [link](#)
- Risk of Parkinson's disease in people aged ≥ 50 years with new-onset anxiety: a retrospective cohort study in UK primary care - [link](#)
- Collaborative discussions between pharmacists and general practitioners to optimise patient medication: a qualitative study within a clinical trial - [link](#)
- Recurrent urinary tract infections and prophylactic antibiotic use in women: cross-sectional study - [link](#)

British Medical Journal (BMJ)

- Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial - [link](#)
- Diagnosis and management of resistant hypertension - [link](#)
- Reducing unnecessary investigations in paediatric seizures in the emergency department - [link](#)
- Colchicine in patients with acute ischaemic stroke or transient ischaemic attack (CHANCE-3): multicentre, double blind, randomised, placebo controlled trial - [link](#)
- SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study - [link](#)
- Trends in cardiovascular disease incidence among 22 million people in the UK over 20 years: population based study - [link](#)
- Clinical Update: Analgesia for non-specific low back pain - [link](#)
- Acute painful crisis in adults with sickle cell disease - [link](#)
- Peer support in chronic health conditions - [link](#)
- Philip Morris: Leaked documents show how company tries to influence science and policy on heated tobacco - [link](#)

BMJ Quality and Safety

- Viewpoint: Need to systematically identify and mitigate risks upon hospitalisation for patients with chronic health conditions - [link](#)

Circulation

- CYP2C19 Genetic Testing for Oral P2Y12 Inhibitor Therapy: A Scientific Statement From the American Heart Association - [link](#)
- Tadalafil for Treatment of Combined Postcapillary and Precapillary Pulmonary Hypertension in Patients With Heart Failure and Preserved Ejection Fraction: A Randomized Controlled Phase 3 Study - [link](#)
- Effect of apixaban on clinical outcomes in outpatients with COVID-19: The APOLLO randomized clinical trial - [link](#)

Cochrane

- Treatments for intractable constipation in childhood - [link](#)

Diabetes Care

- Suicidal Ideation, Suicide Attempts, and Suicide Deaths in Adolescents and Young Adults With Type 1 Diabetes: A Systematic Review and Meta-analysis - [link](#)
- Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial - [link](#)
- Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT - [link](#)
- Hyperglycemic Crises in Adults With Diabetes: A Consensus Report - [link](#)
- The Final Frontier in Diabetes Care: Implementing Research in Real-World Practice - [link](#)
- Excess Risk of Injury in Individuals With Type 1 or Type 2 Diabetes Compared With the General Population - [link](#)
- Health Care Utilization and Costs Associated With Empagliflozin in Older Adults With Type 2 Diabetes - [link](#)
- Effect of 48 Months of Closed-Loop Insulin Delivery on Residual C-Peptide Secretion and Glycemic Control in Newly Diagnosed Youth With Type 1 Diabetes: A Randomized Trial - [link](#)
- Dulaglutide and glomerular hyperfiltration, proteinuria, and albuminuria in youth with type 2 diabetes: post hoc analysis of the AWARD-PEDS study - [link](#)

Drug and Therapeutics Bulletin

- DTB select: Dupilumab for treating chronic obstructive pulmonary disease - [link](#)
- Investing in COPD: biologics or smoking cessation and pulmonary rehabilitation? - [link](#)
- Managing COPD exacerbations in primary care - [link](#)

European Heart Journal

- Management of cardiac sarcoidosis: A clinical consensus statement of the Heart Failure Association, the European Association of Cardiovascular Imaging, the ESC Working Group on Myocardial & Pericardial Diseases, and the European Heart Rhythm Association of the ESC - [link](#)
- Acute myocardial infarction and ischaemic stroke: differences and similarities in reperfusion therapies- a review- [link](#)

European Journal of Hospital Pharmacy

- Natural language processing assisted detection of inappropriate proton pump inhibitor use in adult hospitalised patients - [link](#)
- Prevalence of compliance with PIMDINAC criteria among elderly people living with HIV and in non-infected outpatients with other chronic diseases - [link](#)
- A single harmonised pharmacy process to improve clinical trial set-up times - [link](#)
- Antifungal prophylaxis against invasive Candida and Aspergillus infection in adult heart transplant recipients: protocol for a systematic review and meta-analysis - [link](#)

Heart

- Intracoronary thrombolysis in ST-elevation myocardial infarction: a systematic review and meta-analysis - [link](#)

Internal Medicine Journal

- Tocilizumab use in giant cell arteritis: comparing Pharmaceutical Benefits Scheme eligible and ineligible cases in South Australia - [link](#)

- Tinnitus update: what can be done for the ringing? - [link](#)

International Journal of Clinical Pharmacy

- Identification of seniors at risk (ISAR) score and potentially inappropriate prescribing: a retrospective cohort study - [link](#)
- Genetic influence of meningioma on cisplatin resistance: a Mendelian randomization analysis - [link](#)
- Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data - [link](#)

International Journal for Quality in Health Care

- Use of the DMAIC Lean Six Sigma quality improvement framework to improve beta-lactam antibiotic adequacy in the critically ill - [link](#)

JAMA

- Perioperative Management of Antithrombotic Therapy - [link](#)
- Therapies to Decrease Severe Respiratory Syncytial Virus Illness - [link](#)
- Patient page: What Is Age-Related Macular Degeneration? - [link](#) - What Is Thyroid Cancer? - [link](#)
- Prostate-Specific Antigen Values in Transgender Women Receiving Estrogen - [link](#)
- A More Selective vs a Standard Risk-Stratified, Heparin-Based, Obstetric Thromboprophylaxis Protocol - [link](#)

JAMA Internal Medicine

- Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19 - [link](#)
- Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data - [link](#)
- Time- vs Step-Based Physical Activity Metrics for Health - [link](#)

JAMA Network Open

- Internet and Telephone Support for Discontinuing Long-Term Antidepressants: The REDUCE Cluster Randomized Trial - [link](#)

JAMA Neurology

- Recurrent Ischemic Stroke in Patients with Atrial Fibrillation While Receiving Oral Anticoagulants - [link](#)

JAMA Oncology

- Post-recurrence Treatment in Neoadjuvant or Adjuvant FDA Registration Trials: A Systematic Review - [link](#)
- Survival in Patients with Recurrent Intermediate-Stage Hepatocellular Carcinoma: Sorafenib Plus TACE vs TACE Alone Randomized Clinical Trial - [link](#)
- Current Management of Desmoid Tumors - [link](#)

JAMA Psychiatry

- Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia - [link](#)

Journal of the American College of Cardiology

- Efficacy of Semaglutide by Sex in Obesity-Related Heart Failure with Preserved Ejection Fraction: STEP-HFpEF Trials - [link](#)
- Semaglutide and NYHA Functional Class in Obesity-Related Heart Failure With Preserved Ejection Fraction: The STEP-HFpEF Program - [link](#)

Journal of the American Geriatrics Society

- Antibiotics for delirium in older adults with pyuria or bacteriuria: A systematic review - [link](#)

Journal of Clinical Oncology

- Social Characteristics and Adherence to Adjuvant Endocrine Therapy in Premenopausal Women with Breast Cancer - [link](#)

- Clinical Study Report and Individual Participant Data Transparency for US Food and Drug Administration–Approved Anticancer Drugs: A Call for Systematic Data Availability - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Two instances of successful oral desensitisation following hypersensitivity reaction in a patient receiving osimertinib: a case report - [link](#)

Lancet

- Colorectal cancer - [link](#) ; Gestational diabetes - [series](#) - Neonatal bacterial sepsis - [link](#)
- Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial - [link](#)
- Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis - [link](#)

Lancet Diabetes & Endocrinology

- Early pregnancy HbA1c as the first screening test for gestational diabetes: results from three prospective cohorts - [link](#)

Lancet Global Health

- National, regional, and global trends in insufficient physical activity among adults from 2000 to 2022: a pooled analysis of 507 population-based surveys with 5.7 million participants - [link](#)

Lancet HIV

- Longitudinal evolution of the HIV effective reproduction number following sequential expansion of treatment as prevention and pre-exposure prophylaxis in British Columbia, Canada: a population-level programme evaluation - [link](#)

Lancet Neurology

- Collateral-based selection for endovascular treatment of acute ischaemic stroke in the late window (MR CLEAN-LATE): 2-year follow-up of a phase 3, multicentre, open-label, randomised controlled trial in the Netherlands - [link](#)
- Sleep and sleep disorders in people with Parkinson's disease - [link](#)

Lancet Oncology

- Addition of temsirolimus to chemotherapy in children, adolescents, and young adults with intermediate-risk rhabdomyosarcoma (ARST1431): a randomised, open-label, phase 3 trial from the Children's Oncology Group - [link](#)
- Perioperative nivolumab versus observation in patients with renal cell carcinoma undergoing nephrectomy (PROSPER ECOG-ACRIN EA8143): an open-label, randomised, phase 3 study - [link](#)

Lancet Psychiatry

- Concomitant use of antidepressants and benzodiazepines during pregnancy and associated risk of congenital malformations: a population-based cohort study in Taiwan - [link](#)

Lancet Public Health

- The effects of alcohol container labels on consumption behaviour, knowledge, and support for labelling: a systematic review - [link](#)

Lancet Oncology

- Risks of adverse obstetric outcomes among female survivors of adolescent and young adult cancer in England (TYACSS): a population-based, retrospective cohort study - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Exploring the Significance of Pharmaceutical Care in Mental Health: A Spotlight on Cannabis - [link](#)
- Development of an Educational Brochure about Treatment Options for Pregnant Women with Opioid Use Disorders - [link](#)

- Considering the Possible Role of Pharmacists According to the Presence or Absence of Lifestyle-Related Diseases at the Time of Coronary CT Examination and Trends of Medication Use for These Diseases by Medical Doctors - [link](#)

Medical Journal of Australia

- Contextualising the benefits and risks of anti-amyloid therapy for patients with Alzheimer disease and their care team - [link](#)

Nature Medicine

- Benefits for children with suspected cancer from routine whole-genome sequencing - [link](#)

NEJM Evidence

- Effect of Fenofibrate on Progression of Diabetic Retinopathy - [link](#)

New England Journal of Medicine

- A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia - [link](#)
- Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma - [link](#)
- Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma - [link](#)
- Noninvasive Ventilation for Preoxygenation during Emergency Intubation - [link](#)
- Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors - [link](#)
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity - [link](#)
- Amivantamab plus Lazertinib in Previously Untreated EGFR-Mutated Advanced NSCLC - [link](#)
- Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age - [link](#)
- Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis - [link](#)
- Systemic Light Chain Amyloidosis - [link](#)

Pediatric Quality & Safety

- A Quality Initiative to Improve Appropriate Medication Dosing in Pediatric Patients with Obesity - [link](#)

Pharmaceutical Journal

- Study results suggest greener inhaler propellant (HFA-152a) is therapeutically equivalent to traditional alternatives (HFA-134a) - [link](#)
- 'Beyond weight loss': what is the future of semaglutide? - [link](#)

Pharmacotherapy

- Platelet glycoprotein IIb/IIIa antagonists in ischemic stroke patients without endovascular therapy: A meta-analysis - [link](#)
- Evolving resistance landscape in gram-negative pathogens: An update on β -lactam and β -lactam-inhibitor treatment combinations for carbapenem-resistant organisms - [link](#)
- Thirty-day risk of digoxin toxicity among older adults co-prescribed trimethoprim-sulfamethoxazole versus amoxicillin: A population-based cohort study - [link](#)
- Effect of proton pump inhibitors versus histamine-2 receptor antagonists on acute kidney injury in septic patients at high risk for developing stress ulcers - [link](#)

Prescrire International

- Issue 261- [July 2024](#) includes: Methadone: an analysis of adverse effects reported in France - [link](#)

PROSPERO - International prospective register of systematic reviews

- The Efficacy and Safety of Gene Therapy Approaches in Parkinson's Disease: A Systematic Review - [link](#)
- Association of Proton Pump Inhibitors and Chronic Kidney Disease. A Systematic Review and Meta-analysis - [link](#)
- Meta-analysis: Fostamatinib treatment vs other therapy in refractory immune thrombocytopenia - [link](#)
- Azvudine compared to nirmatrelvir/ritonavir (Paxlovid) in COVID-19: A systematic review and meta-analysis - [link](#)

Stroke

- Dual antiplatelet therapy after embolic stroke of undetermined source: A subgroup analysis of the CHANCE-2 trial - [link](#)

CONSULTATIONS

Pharmacy Board of Australia

- Have your say on the draft Criminal history registration standard and supporting materials, closes 30 July 2024 - [link](#)

TGA

- Consultation: updates to Australian medicine labelling rules to support medicine safety, closes 11 July 2024 - [link](#)

WEBINARS & PODCASTS

Australian Prescriber Podcasts

- [Episode 166](#) – Biologic therapies for severe asthma with persistent type 2 inflammation

MJA Podcasts

- [Episode 21](#): "By the community, for the community"

UPCOMING EVENTS

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- NMS 2024 – save the date, 19 November 2024 - [link](#)

Society of Hospital Pharmacists (SHPA)

- Medicines Management 2024 MM2024, Adelaide, 14-16 November 2024 – [abstract submission](#) closes 15 July 2024 - early-bird [registration](#) closes 11:59pm AEST Thursday 3 October 2024